Retatrutide Side Effects: Clinical Trial Safety Data (2026)
Introduction
Retatrutide has attracted attention because clinical trials have reported substantial weight loss. But when a medicine acts on three hormone receptors at once, its safety profile deserves just as much attention as its results on the scale.
Retatrutide is an investigational medicine developed by Eli Lilly. It activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. These pathways influence appetite, glucose regulation, and energy metabolism. Their combined activity may help explain the weight-loss effects seen in trials, but it also makes careful safety evaluation important.
As of October 2026, retatrutide remains investigational and is not approved for general public use. Phase 3 results now add to the earlier Phase 2 evidence, including data from TRIUMPH-1 and TRIUMPH-2. These studies provide a clearer picture of common side effects, but they cannot answer every question about long-term safety.
Here, we examine what the clinical data actually show, how findings differ between trials, and what remains uncertain.
Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, MedicalBluff may earn a commission at no additional cost to you. As an Amazon Associate I earn from qualifying purchases.
Quick Summary
- Most common side effects: Diarrhoea, nausea, constipation, vomiting, and reduced appetite.
- Dose matters: Some adverse events occurred more often at higher doses, although the pattern differed by symptom and trial.
- Skin sensations: Dysesthesia appeared in Phase 3 trials and was reported more frequently with retatrutide than placebo.
- Heart rate and blood pressure: Phase 2 data showed a dose-related rise in heart rate; Phase 3 TRIUMPH-2 also reported more hypotension in retatrutide groups.
- Cancer concerns: Available trial findings do not establish that retatrutide causes cancer, but limited follow-up cannot rule out every long-term risk.
- Availability: Retatrutide is investigational and is not approved for routine public use as of October 2026.
What Are the Most Common Retatrutide Side Effects?
Gastrointestinal symptoms account for much of the reported side-effect burden. The Phase 3 TRIUMPH-2 results provide useful dose-by-dose figures.
TRIUMPH-2: Reported adverse events over 80 weeks
| Adverse event | Retatrutide 4 mg | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|---|
| Diarrhoea | 27.4% | 33.5% | 33.6% | 13.2% |
| Nausea | 13.7% | 20.8% | 28.0% | 8.0% |
| Constipation | 14.0% | 16.2% | 16.8% | 9.4% |
| Vomiting | 5.5% | 10.2% | 15.7% | 4.2% |
| Decreased appetite | 5.8% | 12.3% | 17.1% | 4.5% |
| Dysesthesia | 4.5% | 5.6% | 7.3% | 0.7% |
Source: TRIUMPH-2, The Lancet; the reported adverse-event figures are also available in Eli Lilly’s official results announcement. These percentages describe trial participants, not an individual’s guaranteed risk.
These numbers show why it is misleading to describe every retatrutide side effect as either rare or inevitable. Nausea, for example, was reported in 28% of participants receiving 12 mg in TRIUMPH-2, while diarrhoea occurred in about one-third of participants in the higher-dose groups.
The placebo group also reported gastrointestinal symptoms. That matters because symptoms can occur for reasons unrelated to the study medicine. Researchers compare treatment and placebo groups to estimate the difference associated with treatment.
Nausea
Nausea is a common reported effect. It may become more noticeable during dose escalation, when the body is adjusting to treatment.
A person experiencing nausea may find that eating large meals makes symptoms harder to tolerate. However, there is no single duration or severity pattern that applies to everyone, and trial averages cannot tell an individual exactly what will happen.
Repeated vomiting, inability to keep fluids down, or signs of dehydration warrant prompt medical assessment.
Diarrhoea and constipation
Retatrutide trials have reported both diarrhoea and constipation. These symptoms may seem contradictory, but they can occur with medicines that influence appetite, gastrointestinal function, and food intake.
Persistent diarrhoea can lead to fluid and electrolyte losses. Severe constipation accompanied by significant abdominal pain, swelling, or vomiting also needs urgent assessment rather than self-treatment.
Vomiting and reduced appetite
Vomiting was reported more often in higher-dose groups in TRIUMPH-2. Reduced appetite was also more frequent at higher doses.
Reduced appetite is part of the intended metabolic effect, but an excessive reduction in food or fluid intake can become a problem. A large change in body weight does not automatically mean that nutrition, hydration, or overall health is being maintained.
What Do the Clinical Trials Tell Us?
It is important to separate Phase 2 findings from Phase 3 results. The studies differed in their participants, duration, doses, and clinical circumstances. Their percentages should not be combined as though they came from one experiment.
Phase 2: The original published safety findings
The 2023 Phase 2 trial published in The New England Journal of Medicine included 338 adults with obesity or overweight and a weight-related condition. Participants received different retatrutide doses or placebo for 48 weeks.
Researchers reported that gastrointestinal adverse events were the most common. These effects were generally mild to moderate, occurred mainly during dose escalation, and were more frequent in some higher-dose groups.
The trial also found that a lower starting dose was associated with fewer gastrointestinal symptoms than a higher starting dose in the study’s dose groups. This is evidence about the trial regimen, not a recommendation for anyone to obtain or adjust retatrutide independently.
Serious adverse events were reported in 4% of participants in both the placebo group and the retatrutide groups overall. Adverse events led to treatment discontinuation in 6%–16% of retatrutide participants, compared with none in the placebo group. These results come from a relatively small trial and should be interpreted in that context.
Read the original Phase 2 study in The New England Journal of Medicine
Phase 3: Newer evidence from TRIUMPH-1 and TRIUMPH-2
The larger Phase 3 programme has provided additional safety information.
The TRIUMPH-1 trial studied adults with overweight or obesity and weight-related complications, without diabetes. In its 12 mg group, nausea was reported in 42.4%, diarrhoea in 32.0%, constipation in 26.1%, vomiting in 25.3%, and dysesthesia in 12.5%. These results were published in The New England Journal of Medicine in September 2026.
TRIUMPH-2 studied adults with overweight or obesity and type 2 diabetes. Its adverse-event rates differed from TRIUMPH-1. For example, nausea at 12 mg was 28.0% in TRIUMPH-2, compared with 42.4% in TRIUMPH-1.
That difference does not necessarily mean one trial’s results are wrong. The populations and study circumstances differed, so the numbers should be compared cautiously rather than averaged together.
Read TRIUMPH-1 in The New England Journal of Medicine
Does the Retatrutide Dose Affect Side Effects?
In several trials, some side effects were more common in higher-dose groups. The clearest example in TRIUMPH-2 is nausea, which increased from 13.7% at 4 mg to 28.0% at 12 mg. Vomiting and decreased appetite also increased across the dose groups.
Other symptoms did not rise in a perfectly linear pattern. Diarrhoea, for example, was reported in 33.5% of the 9 mg group and 33.6% of the 12 mg group. That small difference should not be interpreted as a meaningful dose effect on its own.
From a pharmaceutical perspective, a dose-response relationship is one part of safety assessment. Researchers also consider the timing of symptoms, their severity, whether they resolve, whether participants stop treatment, and whether serious medical outcomes occur.
The dose schedule used in a clinical trial is a controlled research protocol. It is not a do-it-yourself dosing guide. Retatrutide is investigational, and trial schedules should not be used to self-administer a product purchased online.
For more context about the difference between research doses and a medicine’s safety evidence, read our related guide: Retatrutide Dosage: Weekly Dosing, Safety & Clinical Guide.
Dysesthesia: Tingling, Burning, or Unusual Skin Sensations
Dysesthesia means an abnormal or unpleasant sensation. People may describe it as tingling, burning, prickling, or increased sensitivity to touch. The exact experience can vary.
The finding deserves attention because it appeared in more than one Phase 3 trial:
- In TRIUMPH-2, dysesthesia was reported in 4.5% of participants receiving 4 mg, 5.6% receiving 9 mg, and 7.3% receiving 12 mg, compared with 0.7% receiving placebo.
- In TRIUMPH-1, dysesthesia rates were 5.1%, 12.3%, and 12.5% at 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo.
The difference between the trials is important. It would be inaccurate to quote a single percentage as the universal risk of dysesthesia from retatrutide.
These reports also do not, by themselves, establish the precise biological mechanism responsible for the sensation. Anyone experiencing new, persistent, or worsening tingling, burning, weakness, or loss of sensation should seek medical evaluation rather than automatically attributing it to a study medicine.
Heart Rate and Blood Pressure Changes
Heart rate is another safety measure researchers have examined.
In the Phase 2 trial, heart rate increased in a dose-dependent manner, peaked at around week 24, and declined thereafter. That finding is worth monitoring, but it does not prove that every participant will experience a clinically important heart-rate change.
The TRIUMPH-2 results also reported hypotension, or low blood pressure, more frequently in retatrutide groups than in the placebo group. The reported rates were approximately 1% of the 4 mg group, 5% of the 9 mg group, and 6% of the 12 mg group, compared with less than 1% of the placebo group.
Dizziness, fainting, or unusual weakness may have several possible causes, including dehydration or low blood pressure. These symptoms need assessment in context, particularly if they are severe or recurrent.
People should not assume that retatrutide is safe for them simply because they have no known heart condition. The investigational status of the medicine means its full benefit-risk profile remains under study.
Serious Adverse Events: What Is Known So Far?
Most commonly reported side effects in these trials were gastrointestinal, but researchers also monitored serious adverse events, laboratory changes, and reasons for stopping treatment.
In the Phase 2 trial, serious adverse events occurred in 4% of participants in both the placebo and retatrutide groups overall. One participant receiving retatrutide experienced acute pancreatitis as a serious adverse event. The study also reported asymptomatic increases in amylase and lipase in some participants.
In TRIUMPH-2, treatment discontinuation because of adverse events occurred in 3.8% of the 4 mg group, 11.6% of the 9 mg group, and 7.7% of the 12 mg group, compared with 4.9% of the placebo group.
The TRIUMPH-2 report also described seven deaths during the trial: two in the 4 mg group, three in the 9 mg group, one in the 12 mg group, and one in the placebo group. Investigators judged the deaths unrelated to the study intervention. That assessment is important, but it should not be rewritten as proof that a medicine has no possible serious risks.
A trial’s safety findings need to be interpreted using the study’s size, duration, participants, and methods of assessing causality. Ongoing studies and longer follow-up are needed to build a more complete picture.
Anyone experiencing severe or worsening symptoms should seek appropriate medical care rather than assuming that the symptoms are an expected part of treatment.
Does Retatrutide Cause Cancer?
Cancer is a common concern in discussions about medicines that affect hormone-related pathways, but the available evidence needs careful interpretation.
In the 2023 Phase 2 trial, researchers reported no cases of medullary thyroid cancer or C-cell hyperplasia during the study. This is a finding from that trial, not proof that retatrutide carries no cancer risk.
There is an important distinction between not observing a cancer event in a study and establishing that a medicine cannot cause that event. Rare outcomes may not appear in trials with limited participant numbers or follow-up periods. Some cancers also take years to develop, which means an 80-week trial cannot settle every long-term question.
At present, the available evidence does not establish that retatrutide causes cancer. It also does not justify a blanket claim that every possible long-term cancer concern has been ruled out.
Readers should be wary of websites that present either conclusion as certain without explaining the evidence and its limitations.
How Long Do Retatrutide Side Effects Last?
There is no reliable, universal timeline for how long an individual will experience a retatrutide side effect.
In the trials, gastrointestinal symptoms occurred frequently during dose escalation. Lilly’s TRIUMPH-2 report stated that common adverse events were generally mild to moderate and that the majority resolved during treatment.
That does not mean all symptoms disappear quickly or that a person should wait for them to pass. Duration can depend on the symptom, its severity, the individual’s health, and other factors.
For example, mild nausea and persistent vomiting are not equivalent from a safety perspective. Persistent vomiting or diarrhoea can cause dehydration and may require medical attention. Severe or persistent abdominal pain also warrants urgent assessment.
Because retatrutide is investigational, there is not yet a dependable public-use guide that can predict how long each side effect will last for an individual.
What Happens After Stopping Retatrutide?
This is an important question, but the available evidence does not yet provide a complete answer.
Stopping a medicine and the return of appetite, body weight, or metabolic changes are separate issues. A change after treatment ends does not automatically mean that the medicine caused a withdrawal syndrome. Equally, the absence of a clearly established withdrawal syndrome would not prove that every effect disappears immediately.
The Phase 2 study assessed treatment for 48 weeks, while TRIUMPH-2 included a defined post-treatment follow-up period. Those designs do not establish all the possible long-term effects of stopping retatrutide, including what happens to weight, appetite, or side effects over many months.
It would therefore be premature to promise that side effects will end within a fixed number of days or that weight will remain stable after stopping.
Since retatrutide remains investigational, decisions about starting, stopping, or changing treatment belong within an authorized clinical-trial protocol and the care of the study team.
Retatrutide vs. Semaglutide vs. Tirzepatide: Are the Side Effects Similar?
Retatrutide, semaglutide, and tirzepatide act on related hormone pathways, but they are not the same medicine.
- Semaglutide activates the GLP-1 receptor.
- Tirzepatide activates GIP and GLP-1 receptors.
- Retatrutide activates GIP, GLP-1, and glucagon receptors.
Gastrointestinal symptoms are reported with medicines that act on these pathways. However, the fact that the medicines share some effects does not mean their safety profiles are identical.
Retatrutide’s three-receptor activity is part of the scientific rationale for studying it, but a plausible mechanism is not proof that it is safer, more dangerous, or more effective for every individual than an approved alternative.
Comparisons also need to account for differences between clinical trials. Participant characteristics, dose schedules, treatment duration, and how researchers record adverse events can all influence the reported percentages. Comparing numbers from unrelated trials is not a substitute for a direct head-to-head study.
For a broader explanation of how approved incretin medicines differ, see MedicalBluff’s guide to Ozempic vs Wegovy vs Zepbound: 2026 Clinical & Chemistry.
Recommended Reading
If you want to explore the science of obesity and weight regulation in more detail, The Obesity Code by Jason Fung offers additional background on appetite, metabolism, and body weight. Keep in mind that this book is general reading, not a clinical guide to retatrutide or its side effects.
When Should Someone Seek Medical Attention?
Anyone experiencing concerning symptoms during a clinical trial should contact the study team and follow the trial’s safety instructions.
Seek urgent medical assessment for symptoms such as:
- Severe or persistent abdominal pain, especially with repeated vomiting.
- Inability to keep fluids down, very little urination, or other signs of significant dehydration.
- Fainting, severe dizziness, or difficulty staying alert.
- Trouble breathing, swelling of the face or throat, or other signs of a serious allergic reaction.
- New severe weakness, major sensory changes, or other sudden neurological symptoms.
This is not an exhaustive list, and symptoms can have causes unrelated to retatrutide. The key point is not to dismiss severe or worsening symptoms as an expected side effect.
Retatrutide is not approved for routine public use as of October 2026. Products marketed online as retatrutide may have uncertain identity, strength, purity, or storage history. Buying such a product does not provide the safety controls, medical supervision, or product verification used in an authorized clinical trial.
From a pharmaceutical quality perspective, the stated milligram amount alone cannot prove a product’s identity, potency, purity, or sterility. These are separate quality attributes. For more on how medicines are evaluated, see our guide to Pharmaceutical Quality Control: How Drug Quality Is Built & Tested.
Frequently Asked Questions
What is the most common retatrutide side effect? Gastrointestinal symptoms are the most commonly reported effects. In the 2026 TRIUMPH-2 trial, diarrhoea was reported in 27.4%–33.6% of participants across the retatrutide dose groups, while nausea ranged from 13.7% to 28.0%.
Does retatrutide cause hair loss? The major trial results discussed here do not establish a clear retatrutide-specific hair-loss risk. Hair shedding can have many causes, including rapid weight loss, nutritional deficiencies, illness, and other medicines. More evidence would be needed to determine whether retatrutide independently increases the risk.
Can retatrutide increase heart rate? Yes, the Phase 2 trial reported dose-dependent increases in heart rate that peaked around week 24 and declined thereafter. That finding does not establish how often clinically important heart-rate changes may occur in every population, so further safety evidence remains important.
Does retatrutide cause thyroid cancer? Available trial evidence does not establish that retatrutide causes thyroid cancer. The Phase 2 trial reported no cases of medullary thyroid cancer or C-cell hyperplasia during its study period. However, those findings do not rule out every possible long-term risk.
How long do retatrutide side effects last? There is no fixed duration that applies to everyone. Many reported gastrointestinal events occurred during dose escalation, and most adverse events in TRIUMPH-2 were described as mild to moderate, with the majority resolving during treatment. Severe or persistent symptoms need medical assessment.
Are retatrutide side effects worse at higher doses? Some effects, including nausea and vomiting in TRIUMPH-2, were reported more often in higher-dose groups. Other effects did not increase in a perfectly linear pattern. Trial results should not be used to choose a dose independently.
Is retatrutide approved for weight loss in 2026? No. As of October 2026, retatrutide remains investigational and is not approved for routine public use. It is being evaluated in clinical trials, and its complete safety and benefit profile has not yet been established.
Bottom Line
Gastrointestinal symptoms are the most commonly reported effects. In the 2026 TRIUMPH-2 trial, diarrhoea was reported in 27.4%–33.6% of participants across the retatrutide dose groups, while nausea ranged from 13.7% to 28.0%.
The major trial results discussed here do not establish a clear retatrutide-specific hair-loss risk. Hair shedding can have many causes, including rapid weight loss, nutritional deficiencies, illness, and other medicines. More evidence would be needed to determine whether retatrutide independently increases the risk.
Yes, the Phase 2 trial reported dose-dependent increases in heart rate that peaked around week 24 and declined thereafter. That finding does not establish how often clinically important heart-rate changes may occur in every population, so further safety evidence remains important.
Available trial evidence does not establish that retatrutide causes thyroid cancer. The Phase 2 trial reported no cases of medullary thyroid cancer or C-cell hyperplasia during its study period. However, those findings do not rule out every possible long-term risk.
There is no fixed duration that applies to everyone. Many reported gastrointestinal events occurred during dose escalation, and most adverse events in TRIUMPH-2 were described as mild to moderate, with the majority resolving during treatment. Severe or persistent symptoms need medical assessment.
Some effects, including nausea and vomiting in TRIUMPH-2, were reported more often in higher-dose groups. Other effects did not increase in a perfectly linear pattern. Trial results should not be used to choose a dose independently.
No. As of October 2026, retatrutide remains investigational and is not approved for routine public use. It is being evaluated in clinical trials, and its complete safety and benefit profile has not yet been established.
Retatrutide side effects are best understood through clinical data rather than online promises or alarming headlines. Phase 2 and Phase 3 trials consistently identify gastrointestinal symptoms as an important part of the safety profile. The newer evidence also documents dysesthesia and, in TRIUMPH-2, more reports of hypotension than in the placebo group.
The exact rates differ across studies, so no single percentage describes everyone’s risk. The trials provide useful information, but they cannot settle every question about rare events, long-term outcomes, cancer risk, or what happens many months after treatment stops.
From a pharmaceutical quality perspective, I would not judge an investigational medicine by weight-loss figures alone. The identity and quality of the product, the reliability of the clinical evidence, the adverse-event profile, and the length of safety follow-up all matter. Until retatrutide receives the required regulatory review and approval, it should not be treated as an established option for self-directed weight loss.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The New England Journal of Medicine. 2023. Read the original study.
- Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Published online September 29, 2026; issue dated October 10–16, 2026. Read the study.
- Eli Lilly and Company. TRIUMPH-2 Phase 3 results and safety findings. September 2026. Read the official company announcement.
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). The New England Journal of Medicine. Published September 29, 2026. Read the study.
- Eli Lilly and Company. What to Know About Retatrutide. Updated September 2026. Read the official update.
Medical disclaimer: This article is for educational purposes only and is not a substitute for individual medical advice. Retatrutide remains investigational and is not approved for public use.
